Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

癌症研究 嵌合抗原受体 淋巴瘤 CD19 细胞培养 T细胞 CD28 离体 PI3K/AKT/mTOR通路 免疫学 体内 抗原 医学 生物 细胞生物学 信号转导 免疫系统 生物技术 遗传学
作者
Molly Perkins,Shannon Grande,Amanda Hamel,Holly M. Horton,Tracy E. Garrett,Sara M. Miller,Howard J. Latimer,Christopher Horvath,Michael Kuczewski,Kevin M. Friedman,Richard A. Morgan
出处
期刊:Blood [American Society of Hematology]
卷期号:126 (23): 1893-1893 被引量:21
标识
DOI:10.1182/blood.v126.23.1893.1893
摘要

Patients treated with chimeric antigen receptor (CAR) T cells targeting CD19 for B cell malignancies have experienced rapid and durable tumor regressions. Manufacture of CAR T cells is challenged by the necessity to produce a unique drug product for each patient. Each treatment requires ex vivo culture of patient T cells to facilitate CAR gene transfer and to achieve therapeutic amounts of T cells. Paradoxically, ex vivo culture with IL-2 also decreases CAR T cell activity. Some investigators have proposed isolating central memory T cells (thought to be enriched for therapeutic T cells), yet isolation techniques are cumbersome and costly to scale commercially. Culture of T cells in IL-7 and IL-15 has also been shown by several investigators to improve therapeutic activity. Here we explored the potential for culture modifications to improve the therapeutic potential of CAR T cells without adding complexity to manufacturing. We tested this hypothesis using CAR T cells specific to B cell maturation antigen (BCMA) manufactured using standard IL-2 culture with an inhibitor of PI3K added to the media, or with IL-7 and IL-15 in place of IL-2. The in vivo activity was studied in NSG mouse models of human Burkitt9s lymphoma (Daudi), and multiple myeloma (RPMI-8226), both of which express BCMA. In the lymphoma model, NSG mice were injected intravenously (IV) with 2 x 10 6 Daudi cells and allowed to accumulate a large tumor burden before being treated with 4 x 10 6 CAR+ T cells on day 18 post-tumor injection. At this late time point post implantation, mice had highly disseminated Daudi tumor (our goal was to model late stage disease observed in relapsed and refractory lymphoma). In this model of advanced disease, IL-2 cultured anti-BCMA CAR T cells had no effect on tumor growth (p = 0.22) and all mice succumbed to the tumors within two weeks after treatment. Anti-BCMA CAR T cells grown in IL-7 and IL-15 also failed to control tumor growth (p = 0.23). In sharp contrast, all animals treated with anti-BCMA CAR T cells cultured with the PI3K inhibitor survived and experienced complete long-term tumor regression (p=0.003). The same anti-BCMA CAR T cells were used in a model of multiple myeloma. NSG mice were injected subcutaneously (SC) with 10 7 RPMI-8226 MM cells, and at 22 days post-implantation mice received a single IV administration of anti-BCMA CAR T cells (4 x 10 5 CAR+ T cells/mouse) cultured under various conditions. In this model, all treatment groups demonstrated tumor regression, regardless of the in vitro culture conditions. To evaluate CAR T cell durability, two weeks after initial tumor clearance, surviving animals were then re-challenged with RPMI-8226 cells on the opposite flank to model tumor relapse. We found that only animals that had been treated with anti-BCMA CAR T cells cultured with PI3K inhibition were immune to subsequent tumor challenge (p=0.005). Given the superior in vivo efficacy of anti-BCMA CAR T cells cultured with PI3K inhibition, we sought to identify phenotypic characteristics associated with the improved therapeutic activity. Anti-BCMA CAR T cells cultured with PI3K inhibition contained an increased frequency of CD62L+ CD8 T cells in the final product (p ex vivo expansion with IL-2 may generate a superior anti-BCMA CAR T cell product for clinical use. Furthermore, this approach could potentially be used in the manufacture of other T cell therapies. Disclosures Perkins: bluebird bio: Employment, Equity Ownership. Grande: bluebird bio: Employment, Equity Ownership. Hamel: bluebird bio: Employment, Equity Ownership. Horton: bluebird bio: Employment, Equity Ownership. Garrett: bluebird bio: Employment, Equity Ownership. Miller: bluebird bio: Employment, Equity Ownership. Latimer: bluebird bio: Employment, Equity Ownership. Horvath: bluebird bio: Employment, Equity Ownership. Kuczewski: bluebird bio: Employment, Equity Ownership. Friedman: bluebird bio: Employment, Equity Ownership. Morgan: bluebird bio: Employment, Equity Ownership.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘒彼小星完成签到 ,获得积分10
刚刚
可爱的函函应助XinyiZhang采纳,获得10
刚刚
积极的板栗完成签到,获得积分10
刚刚
yipyip完成签到,获得积分20
2秒前
2秒前
许win发布了新的文献求助10
2秒前
不可思宇完成签到,获得积分10
2秒前
4秒前
5秒前
111完成签到,获得积分10
5秒前
传奇3应助信封采纳,获得10
5秒前
研友_8Wq6Mn发布了新的文献求助10
6秒前
派大凯不是俺完成签到,获得积分10
7秒前
7秒前
黄紫红完成签到 ,获得积分10
8秒前
赘婿应助直率翠绿采纳,获得10
8秒前
bbbbbbbbs完成签到,获得积分10
9秒前
简单寄云完成签到,获得积分20
10秒前
123完成签到,获得积分10
10秒前
葡萄炖雪梨完成签到 ,获得积分10
10秒前
12秒前
独特一刀发布了新的文献求助10
12秒前
zhang08发布了新的文献求助10
13秒前
13秒前
澳門大三八完成签到,获得积分10
14秒前
14秒前
Owen应助江边鸟采纳,获得20
14秒前
14秒前
16秒前
16秒前
汀烟发布了新的文献求助10
19秒前
19秒前
聂瑛完成签到,获得积分10
19秒前
华仔应助热心的乞采纳,获得10
20秒前
动听涔雨发布了新的文献求助10
20秒前
安古妮稀完成签到,获得积分10
20秒前
FashionBoy应助简单寄云采纳,获得10
21秒前
luoshi94发布了新的文献求助40
22秒前
szbllc发布了新的文献求助30
22秒前
yinlu完成签到 ,获得积分10
23秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 870
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Fundamentals of Dispersed Multiphase Flows 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3254496
求助须知:如何正确求助?哪些是违规求助? 2896621
关于积分的说明 8293567
捐赠科研通 2565575
什么是DOI,文献DOI怎么找? 1393151
科研通“疑难数据库(出版商)”最低求助积分说明 652436
邀请新用户注册赠送积分活动 629972